The Patent Finder

Treatment of Gout and Hyperuricemia

Ardea Biosciences, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,216,179Treatment of Gout and Hyperuricemia
In force
 · High confidence
Ardea Biosciences, Inc.In forceHigh confidence
Application 14/939,963Treatment of Gout and Hyperuricemia
Abandoned
Abandoned Jul 23, 2017
Ardea Biosciences, Inc.AbandonedAbandoned Jul 23, 2017
Application 15/624,818Treatment of Gout and Hyperuricemia
Abandoned
Abandoned Jan 29, 2018
Ardea Biosciences, Inc.AbandonedAbandoned Jan 29, 2018
Application 15/878,679Treatment of Gout and Hyperuricemia
Abandoned
Abandoned Sep 21, 2018
Ardea Biosciences, Inc.AbandonedAbandoned Sep 21, 2018
Application 16/135,153Treatment of Gout and Hyperuricemia
Abandoned
Abandoned Dec 12, 2018
Ardea Biosciences, Inc.AbandonedAbandoned Dec 12, 2018
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Ardea Biosciences, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited